Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious infections. Co. is developing tedizolid phosphate, an antibiotic, for the treatment of Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, and pneumonia, and potentially for other indications. Co.'s other product candidates include: its GyrB/ParE preclinical program, in which Co. is developing broad-spectrum agents that include those important Gram-negative pathogens for biodefense.